Introduction
Cellular senescence is a state with permanent loss of replicative capability even upon mitogenic stimuli. Cellular senescence is characterized by phenotypic alterations including induction of senescence-associated b-galactosidase (SA-b-gal), a large and flat cell morphology and increased expression of plasminogen activator inhibitor 1 (PAI-1) (Goldstein et al., 1994; Dimri et al., 1995) .
Immortalization, an escape from the replicative senescence program, is a necessary step for neoplastic transformation of cells. Hence, transformed cells can bypass the replicative senescence program. However, cancer and leukemia cells still retain the capacity to undergo premature senescence in response to various stimuli. Senescent normal human fibroblasts usually exhibit G1 cell cycle arrest. However, polyploidy and multinucleation are also associated with replicative senescence and premature senescence in various cell types, including human normal endothelial cells (Aviv et al., 2001; Wagner et al., 2001 ) and breast cancer MCF-7 cells .
Anticancer chemotherapeutic agents and ionizing radiation have been shown to cause senescence-like growth arrest in human cancer cells in vitro and in vivo (Han et al., 2002; Schmitt et al., 2002; te Poele et al., 2002; Shay and Roninson, 2004) . Induction of SA-b-gal staining by chemotherapy was observed in vivo in cancer and lymphoma cells in rodents (Elmore et al., 2002; Roninson, 2002; Schmitt et al., 2002; Christov et al., 2003) and in patients with breast cancer (te Poele et al., 2002) . Thus, senescence-like growth arrest has been proposed to be a putative determinant of in vivo tumor response to chemotherapeutic agents and ionizing radiation (Mathon and Lloyd, 2001; Wang et al., 2003; Ben-Porath and Weinberg, 2004; Kahlem et al., 2004; Pelicci, 2004; Sharpless and DePinho, 2004; Shay and Roninson, 2004) .
Sirt1 is a mammalian NAD þ -dependent deacetylase that belongs to class III histone deacetylases (HDACs) (Imai et al., 2000; Landry et al., 2000; Blander and Guarente, 2004) . Sir2, yeast homologue of Sirt1, is involved in a number of cellular processes including gene silencing at telomere and mating loci, DNA repair, recombination and aging. Recent studies demonstrated that Sirt1 plays an important role in the regulation of cell fate and stress response in mammalian cells. Sirt1 promotes cell survival by inhibiting apoptosis or cellular senescence induced by stresses including DNA damage and oxidative stress. An increasing number of proteins have been identified as substrates of Sirt1, including p53 (Luo et al., 2001; Vaziri et al., 2001; Langley et al., 2002) , FOXO transcription factors (Brunet et al., 2004; Daitoku et al., 2004; Motta et al., 2004; van der Horst et al., 2004) , peroxisome proliferator-activated receptor-g (Picard et al., 2004) and Ku70 (Cohen et al., 2004) .
Sirt1 deacetylase, a member of the class III HDAC family, exhibits distinct biochemical characteristics from conventional class I and class II HDACs. Inhibitors for class I and class II HDACs, such as trichostatin A and its derivatives, do not inhibit the deacetylating activity of Sirt1 (Imai et al., 2000) . Conversely, specific inhibitors for Sirt1 such as Sirtinol do not inhibit class I and class II HDACs, either (Bedalov et al., 2001; Grozinger et al., 2001) .
Class I and class II HDAC inhibitors exhibit antiproliferative effects in human cancer cells (Rosato and Grant, 2004; Vanhaecke et al., 2004; Vigushin and Coombes, 2004) . The efficacy of class I and class II HDAC inhibitors for treatment of patients with cancer or leukemia has been examined in phase I and II clinical trials (Piekarz et al., 2001; Sandor et al., 2002; Kelly et al., 2003; McLaughlin and La Thangue, 2004; Piekarz and Bates, 2004) . However, the effects of inhibitor for Sirt1 or class III HDACs on cell growth have not yet been investigated. Here, we show that Sirtinol, a specific inhibitor for Sirt1, induced senescence-like growth arrest in human breast cancer MCF-7 and lung cancer H1299 cells, and that Sirtinol-induced senescence-like growth arrest was accompanied by blunted activation of Rasmitogen-activated protein kinase (MAPK) pathways in response to growth factors.
Results
Sirtinol, Sirt1 inhibitor, induced senescence-like growth arrest in human MCF-7 and H1299 cells MCF-7 and H1299 cells were exposed to Sirtinol (100 mM) for 24 h; then Sirtinol was removed from the culture media. Treatment with Sirtinol inhibited cell growth in both MCF-7 and H1299 cells (Figure 1a and b). The inhibition of cell growth was persistent and observed up to 9 days after Sirtinol withdrawal. These results suggest that Sirtinol caused a sustained growth arrest. This was supported by reduced incorporation of BrdU in Sirtinol-treated MCF-7 and H1299 cells at 10 days after the addition of Sirtinol, as compared with untreated cells (Figure 1c and d) .
We examined the effects of Sirtinol treatment on SAb-gal activity and the expression of PAI-1, characteristic features of senescence-like growth arrest. Sirtinol treatment increased SA-b-gal-positive cells in a dose-dependent manner 10 days after the addition of Sirtinol in both MCF-7 and H1299 cells (Figures 2 and 3a) , but the extent of SA-b-gal induction was relatively smaller in H1299 than in MCF-7 cells. Only a small number of MCF-7 and H1299 cells were SA-b-gal-positive when untreated. Enlarged, flattened morphology was Sirt1 inhibitor-induced senescence-like growth arrest H Ota et al observed in Sirtinol-treated MCF-7 cells and, to a lesser extent, in Sirtinol-treated H1299 cells, as compared with untreated cells. Sirtinol treatment also resulted in increased expression of PAI-1 in both MCF-7 and H1299 cells (Figure 3b ). b-Actin expression, however, was not affected by Sirtinol.
Treatment with Splitomicin, another specific inhibitor for Sirt1, for 24 h also led to the induction of SA-b-gal staining in a dose-dependent manner (Figure 3a) . However, greater concentrations of Splitomicin appeared to be required to induce SA-b-gal, as compared with Sirtinol.
Colony formation assay also revealed that both Sirtinol and Splitomicin elicited antiproliferative effects in MCF-7 and H1299 cells in a dose-dependent manner (Figure 4 ). Sirtinol inhibited colony formation at concentrations of 33 mM and higher in MCF-7 and H1299 cells. On the other hand, 33 mM Splitomicin failed to decrease the number of colonies, but Splitomicin at 100 and 333 mM effectively inhibited colony formation in MCF-7 and H1299 cells.
Senescence-like growth arrest by Sirt1 inhibition was further corroborated by experiments using short interfering RNA (siRNA). Gene knockdown of Sirt1 by siRNA resulted in induction of SA-b-gal staining, large and flat cell morphology, decreased BrdU incorporation and increased PAI-1 expression in both MCF-7 and H1299 cells, as compared with control siRNA ( Figure 5 ). Moreover, Sirt1 inhibition by Sirtinol, Splitomicin or siRNA also induced senescence-like phenotype in human diploid fibroblasts, WI-38 and IMR-90 cells, reflected by induction of SA-b-gal staining, and enlarged and flattened cell morphology (Supplementary Figure 1) .
In Sirtinol-treated MCF-7 cells, the number of multinucleated cells was increased compared with untreated cells (Figure 2 ), but multinucleated cells were not found in H1299 cells regardless of whether treated with or without Sirtinol. Consistent with these observations, flow cytometric analysis revealed that the substantial cell population of Sirtinol-treated MCF-7 cells exhibited DNA content over 4N, indicative of polyploidy ( Figure 6a ). Polyploidy fraction estimated by the ratio In cellular senescence, induction of p53, dephosphorylation of Rb and increased expression of cyclindependent kinase inhibitors such as p16, p21 and p27 have been shown to be involved (Serrano et al., 1997; Collado et al., 2000; Alexander and Hinds, 2001; Beausejour et al., 2003; Jirawatnotai et al., 2003; Mallette et al., 2004) . We found that phosphorylated Rb was decreased in Sirtinol-treated MCF-7 and H1299 cells compared with untreated cells, while the protein expression of Rb was unaltered (Figure 7a and b). p27 expression was induced in Sirtinol-treated MCF-7 and H1299 cells (Figure 7f and g), while b-actin expression was unaltered. However, the mRNA level of p27 was not increased by Sirtinol treatment in MCF-7 and H1299 cells at both 3 and 10 days after the addition of Sirtinol, while tamoxifen and serum starvation upregulated the p27 mRNA level in MCF-7 and H1299 cells, respectively (Supplementary Figure 2) . In contrast, p21 was not increased in Sirtinol-treated MCF-7 and H1299 cells compared with untreated cells. p16 was not induced in Sirtinol-treated H1299 cells (Figure 7g ). MCF-7 and H1299 cells are deficient in p16 and p53, respectively. On the other hand, treatment with tamoxifen (1 mM) for 24 h increased protein expression of p21 and p27 in MCF-7 cells, and serum starvation for 24 h induced p16, p21 and p27 expression in H1299 cells. Neither expression nor acetylation of p53 was upregulated by Sirtinol (Figure 7e ). These results are consistent with previous observations that inhibition of Sirt1 by itself did not induce p53 acetylation in the absence of other stimulus, while DNA damage-or oxidative stress-induced p53 acetylation was accentuated by Sirt1 inhibition (Luo et al., 2001; Vaziri et al., 2001; Langley et al., 2002; Cheng et al., 2003) .
Senescence-like growth arrest was accompanied by attenuated activation of MAPK pathways in response to growth factors We examined the activation status of signaling pathways of MAPKs and Akt/PKB in response to growth factors, epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I). When untreated with Sirtinol, upon exposure to EGF or IGF-I, robust phosphorylation of extracellular-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK/SAPK, also termed stressactivated protein kinase) and p38 MAPK was observed in MCF-7 and H1299 cells. By contrast, in Sirtinoltreated senescent MCF-7 and H1299 cells at 10 days after the addition of Sirtinol (100 mM), basal (unstimulated) phosphorylation of ERK, JNK/SAPK and p38 MAPK was reduced compared with untreated cells (Figure 8 ). In addition, EGF-or IGF-I-stimulated phosphorylation of ERK, JNK/SAPK and p38 MAPK was attenuated in MCF-7 and H1299 cells at 10 days after the addition of Sirtinol, compared to untreated cells. Reduced activation of ERK, JNK/SAPK and p38 MAPK was corroborated by the phosphorylation status of the endogenous substrates of these MAPKs. Basal (unstimulated) as well as EGF-or IGF-I-stimulated phosphorylation of Elk-1, c-Jun and ATF-2 was also decreased in Sirtinol-treated senescent MCF-7 and H1299 cells at 10 days after the addition of Sirtinol, compared with untreated cells (Figure 9 ). The protein expression of ERK, JNK/SAPK, p38 MAPK, Elk-1, c-Jun and ATF-2 did not differ between Sirtinol-treated and untreated MCF-7 and H1299 cells.
However, at 3 days after the addition of Sirtinol, unlike at 10 days after the inhibitor addition, EGFstimulated phosphorylation of ERK, JNK/SAPK and p38 MAPK was not attenuated in MCF-7 cells, compared with untreated cells (Figure 8d ). These results suggest that attenuated MAPK pathways may be a consequence, rather than a cause, of Sirtinol-induced commitment of senescence-like growth arrest.
In contrast, tyrosine phosphorylation of the receptors for EGF and IGF-I by their ligands was not altered by Sirtinol treatment in MCF-7 and H1299 cells at 10 days after the addition of Sirtinol (Figure 10 ). The expression of EGF receptor and IGF-I receptor did not differ between Sirtinol-treated and untreated cells. These findings suggest that the defects responsible for impaired activation of MAPKs may exist at the level(s) of postreceptor signaling cascades.
Ras plays a critical role in growth factor-stimulated activation of MAPK pathways. Active Ras was markedly increased by EGF in untreated MCF-7 and H1299 cells. In Sirtinol-treated senescent MCF-7 and H1299 cells, however, the basal (unstimulated) level of active Ras was reduced compared with untreated cells, and EGF failed to increase active Ras (Figure 11a ). Consistent with defective activation of Ras, basal (unstimulated) and EGF-or IGF-I-stimulated phosphorylation of Raf-1, MEK, SEK1/MKK4 and MKK7 was attenuated in Sirtinol-treated cells relative to untreated cells (Figure 11b ). However, no difference was found between Sirtinol-treated and untreated MCF-7 and H1299 cells in the protein expression of Ras, Raf-1, MEK, SEK1/MKK4 and MKK7. Figure 8 Growth factor-stimulated phosphorylation of MAPKs in Sirtinol-treated cells. (a-c) At 10 days after the addition of Sirtinol (100 mM), following overnight serum starvation, the cells were exposed to EGF (50 ng/ml) for 10 or 20 min (a, b), or to IGF-I (100 ng/ml) for 10 min (c). In untreated (Control) MCF-7 and H1299 cells, marked phosphorylation of ERK, JNK/SAPK and p38 MAPK was induced by EGF or IGF-I. In Sirtinol-treated MCF-7 and H1299 cells, basal (unstimulated) as well as EGF-and IGF-I-stimulated phosphorylation of ERK, JNK/SAPK and p38 MAPK was decreased compared with untreated cells. (d) At 0, 3 and 10 days after the addition of Sirtinol (100 mM), MCF-7 cells were stimulated with EGF (50 ng/ml) for 20 min. EGF-stimulated phosphorylation of ERK, JNK/SAPK and p38 MAPK was markedly impaired at 10 days, but preserved at 3 days after the addition of Sirtinol.
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In contrast to the Ras-MAPK pathway, EGF-or IGF-I-induced as well as basal (unstimulated) phosphorylation of Akt/PKB was not decreased in Sirtinoltreated senescent MCF-7 and H1299 cells compared with untreated cells at 10 days after Sirtinol addition (Figure 12 ). The expression of Akt/PKB was not altered by Sirtinol treatment, either.
Discussion
We found that Sirt1 inhibition by specific inhibitors, Sirtinol and Splitomicin, and siRNA caused senescencelike growth arrest in human cancer MCF-7 and H1299 cells, as judged by SA-b-gal staining, PAI-1 expression, BrdU incorporation, flattened and enlarged morphology of the cells and flow cytometric analysis (Figures 1-6 ). Sirtinol-induced senescence-like growth arrest was accompanied by attenuated responses to growth factors in terms of activation of Ras-MAPKs (Figures 8, 9 and 11). By contrast, phosphorylation (activation) of EGF receptor, IGF-I receptor and Akt/PKB by growth factors was not affected in Sirtinol-treated senescent MCF-7 and H1299 cells (Figures 10 and 12) .
Consistent with impaired activation of MAPKs, EGF-and IGF-I-stimulated phosphorylation of downstream targets, Elk-1, c-Jun and ATF-2, was also reduced (Figure 9) . A hallmark feature of senescent cells is unresponsiveness to mitogenic stimuli in terms of induction of c-fos as well as cell proliferation. Previous studies in senescent human diploid fibroblasts showed that induction of c-fos (Seshadri and Campisi, 1990 ) and activation of Elk-1 (Tresini et al., 2001 ) and MEK-ERK (Torres et al., 2003) in response to growth factors are impaired. Transcriptional activity of Elk-1 regulates the induction of c-fos, an immediate early gene. Thus, our results of attenuated activation of Ras-MEK-ERKElk-1 in Sirtinol-treated senescent cancer cells are in agreement with previous findings in senescent human fibroblasts.
Our results indicate that the signaling defect in Sirtinol-treated cells is specific for MAPK pathways and that the PI3-K-Akt/PKB pathway is preserved. Ras is a key regulator of MAPK pathways (Lange-Carter and Johnson, 1994) . However, Ras does not play a major role in activation of the PI3-K-Akt/PKB pathway (Sakaue et al., 1995; Gnudi et al., 1997; Klesse et al., 1999) . Our results showed that active, GTP-bound Ras was reduced in Sirtinol-treated cancer cells compared with untreated cells (Figure 11a ). The present data, therefore, suggest that reduced activation of Ras might be involved in a specific attenuation in MAPK pathways in Sirtinol-treated senescent MCF-7 and H1299 cells.
Growth factor-initiated mitogenic signals are conveyed mainly by two major signaling cascades: Ras-ERK and PI3-K-Akt/PKB. Senescent cells remain viable and metabolically active, in spite of irreversible loss of replication capability (Roninson, 2003; Shay and Roninson, 2004) . One can reasonably speculate, therefore, that the preserved PI3-K-Akt/PKB pathway might Figure 9 Growth factor-stimulated phosphorylation of Elk1, c-Jun and ATF2. At 10 days after the addition of Sirtinol (100 mM), following overnight serum starvation, the cells were exposed to EGF (50 ng/ml) for 10 or 20 min (a, b) or to IGF-I (100 ng/ml) for 10 min (c). In untreated (Control) MCF-7 and H1299 cells, marked phosphorylation of Elk1, c-Jun and ATF2 was induced by EGF and IGF-I. In Sirtinol-treated MCF-7 and H1299 cells, both basal (unstimulated) and EGF-or IGF-I-stimulated phosphorylation of Elk1, c-Jun and ATF2 were decreased compared with untreated cells. Figure 10 Growth factor-stimulated phosphorylation of EGF receptor and IGF-I receptor in Sirtinol-treated cells. At 10 days after the addition of Sirtinol (100 mM), following overnight serum starvation, the cells were exposed to EGF (50 ng/ml) (a) or IGF-I (100 ng/ml) for 2 min (b). There was no difference in tyrosine phosphorylation and protein expression of EGF receptor (EGFR) and IGF-I receptor (IGFR) between Sirtinol-treated and untreated (Control) MCF-7 and H1299 cells.
Sirt1 inhibitor-induced senescence-like growth arrest H Ota et al contribute to cell viability and metabolic activities in Sirtinol-treated cells, because the PI3-K-Akt/PKB pathway plays critical roles in cell survival and regulation of metabolism. p53, Rb and cyclin-dependent kinase inhibitors such as p16, p21 and p27 have been recognized as key mediators of cellular senescence (Serrano et al., 1997; Collado et al., 2000; Alexander and Hinds, 2001; Beausejour et al., 2003; Jirawatnotai et al., 2003; Mallette et al., 2004) . Our results showed that hypophosphorylation of Rb and increased expression of p27 were associated with Sirtinol-induced senescence-like growth arrest in MCF-7 and H1299 cells (Figure 7) . In addition to regulation at transcriptional level, increased p27 expression may result from reduced protein degradation through a ubiquitin-proteasome system (Carrano et al., 1999) . Since Sirt1 is an HDAC, it is possible that Sirt1 inhibition may directly modulate p27 transcription. However, our finding of unaltered p27 mRNA in Sirtinol-treated cells (Supplementary Figure 2) suggests that decreased protein degradation of p27, rather than increased transcription, may contribute to increased p27 protein expression in Sirtinol-treated cells. Thus, our data argue against a direct effect of Sirtinol on transcription of p27.
On the other hand, we did not find increased expression of p53, p21 and p16 in Sirtinol-treated MCF-7 and H1299 cells. It is important to note, however, that previous studies showed that premature senescence can be readily induced independent of p53, Figure 11 Activation status of Ras and its downstream signaling molecules in Sirtinol-treated cells. At 10 days after the addition of Sirtinol (100 mM), following overnight serum starvation, the cells were exposed to EGF (50 ng/ml) for 10 or 20 min, or IGF-I (100 ng/ml) for 10 min. 
Figure 12
Growth factor-stimulated Akt/PKB phosphorylation in Sirtinol-treated cells. At 10 days after the addition of Sirtinol (100 mM), following overnight serum starvation, the cells were exposed to EGF (50 ng/ml) for 10 or 20 min (a, b) or to IGF-I (100 ng/ml) for 10 min (c). No difference was found in basal (unstimulated) and EGF-or IGF-I-stimulated phosphorylation of Akt/PKB between Sirtinol-treated and untreated (Control) MCF-7 and H1299 cells.
Sirt1 inhibitor-induced senescence-like growth arrest H Ota et al p21 or p16 in cancer cells (Zhu et al., 1997; Chang et al., 1999a, b; Collado et al., 2000; Wainwright et al., 2001; Wright and Shay, 2001; te Poele et al., 2002; Beausejour et al., 2003; Mallette et al., 2004; Munro et al., 2004) . p27 was shown to be required for premature senescence mediated by Rb (Alexander and Hinds, 2001) or PI3-K inhibitor (Collado et al., 2000) . In accordance with previous findings (Chang et al., 1999a; Collado et al., 2000; Wainwright et al., 2001; Mallette et al., 2004) , Sirtinol induced senescence-like growth arrest in p16-deficient MCF-7 and p53-deficient H1299 cells. These results indicate that p53 and p16 are not required for Sirtinol-induced senescence-like growth arrest in H1299 and MCF-7 cells, respectively.
Recently, senescence-like growth arrest has been proposed as a new target of cancer therapy. Since p53 and p16 are not expressed or mutated in many types of malignancies, the effectiveness of Sirtinol to induce senescence-like growth arrest in p53-and p16-deficient cancer cells may be of clinical significance for the treatment of patients with malignancy. Taken together, the present study highlights Sirt1 inhibitor as an antitumor drug candidate.
Materials and methods

Materials
Sirtinol, Splitomicin, IGF-I, EGF (Calbiochem, La Jolla, CA, USA), trichostatin A, cisplatin, propidium iodide, RNase, tamoxifen (Sigma, St Louis, MO, USA), anti-phospho-ERK (Thr202/Tyr204), ERK, phospho-JNK/SAPK (Thr183/Tyr185), phospho-p38 (Thr180/Tyr182), p38, phospho-Raf (Ser259), Raf-1, phospho-MEK1/2 (Ser217/221), MEK1/2, phospho-SEK1/MKK4 (Ser80), SEK1/MKK4, MKK7, phospho-Elk1 (Ser383), Elk1, phospho-ATF2 (Thr71), ATF2, phospho-Rb (Ser795), Rb, phospho-Akt (Ser473), Akt, p53 (Cell Signaling, Beverly, MA, USA), acetylated p53, EGFR, phospho-MKK7 (Thr275/Ser277) (Upstate, Lake Placid, NY, USA), phospho-EGFR (Tyr1173), p16, p21, phospho-c-Jun (Ser63), c-Jun, JNK1 (Santa Cruz, Santa Cruz, CA, USA), p27 (BD Transduction Laboratories, Lexington, KY, USA), PAI-1 (Molecular Innovations, Southfield, MI, USA), acetylated histone H3, histone H3 (Upstate, Charlottesville, VA, USA), phospho-IGF-I receptor (Tyr1162/1163), IGF-I receptor (Biosource, Camarillo, CA, USA) and pan-Ras antibodies (Oncogene, San Diego, CA, USA) were purchased commercially.
Cell culture
Human breast cancer MCF-7 cells and non-small lung cancer H1299 cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (DMEM) and RPMI 1640 supplemented with 10% fetal bovine serum (FBS, Sigma), respectively. Logarithmically growing cells were treated with the indicated concentrations of Sirtinol or Splitomicin for 24 h. After exposure to Sirtinol or Splitomicin for 24 h, the cells were washed three times with inhibitor-free medium and cultured for an additional 9 days with the complete media in the absence of inhibitor. Cell viability was determined by the Trypan blue exclusion test, and viable cells were counted. At 9 days after the addition of Sirtinol to the culture media, the cells were serum-deprived for overnight, and then treated with EGF (50 ng/ml) or IGF-I (100 ng/ml) for 2, 10 or 20 min.
SA-b-gal staining SA-b-gal staining was performed as previously described (Dimri et al., 1995) (see Supplementary section).
BrdU incorporation assay
At 10 days after the addition of Sirtinol, BrdU incorporation was assayed as previously described (Takahashi et al., 1992) . In cells treated with siRNA, at 10 days after the transfection of siRNA, BrdU incorporation was evaluated using a commercial kit (Roche, Indianapolis, IN, USA).
Gene knockdown with siRNA Cells were plated in six-well plates at 20-30% confluency, and 24 h later transfected with 200 pmol of siRNA for Sirt1 ( 0 5-GAT GAA GTT GAC CTC CTC A-3 0 (Picard et al., 2004) and 5 0 -TGA AGT GCC TCA GAT ATT A-3 0 ) or control siRNA (Dharmacom, Chicago, IL, USA), using siIMPORTER (Upstate).
Flow cytometric analysis
At 10 days after the addition of Sirtinol, the cells were fixed with 70% ethanol and treated with 5 mg/ml (RNase) for 30 min. After staining with 50 mM propidium iodide, the cells were subjected to flow cytometric analysis with FACS Calibur and Cell Quest software (Becton-Dickinson, Franklin Lakes, NJ, USA).
Immunoblot analysis
Immunoblot analysis was performed as previously described 
(see Supplementary section).
Determination of activation status of Ras Active, GTP-bound Ras was assayed using the Ras activation assay kit (Upstate) according to the manufacturer's instructions (see Supplementary section).
Colony formation assay
Colony formation assay was performed as previously described (Elegbede et al., 2002 ) (see Supplementary section).
Northern blotting
The mRNA level of p27 was evaluated by Northern blotting as previously described , using cDNA probe for p27 that was kindly provided by Dr N Fujita (Fujita et al., 2002) .
